

Kazuistiky v onkologii 2013

- 2 **Votrient – nový multikinázový inhibitor v léčbě renálního karcinomu**
MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha
- 2 **Neuroendokrinní nádory – léčba Sandostatinem LAR**
MUDr. Oldřich Louthan IV. interní klinika, Centrum pro neuroendokrinní nádory,
Všeobecná fakultní nemocnice, 1. LF UK, Praha
- 2 **Pacientka s již primárně diseminovaným HER2 pozitivním karcinomem prsu**
MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 3 **Pacient s metastatickým kolorektálním karcinomem léčený multimodálním přístupem**
MUDr. Andrea Jurečková | MUDr. Jiří Tomášek | prof. MUDr. Rostislav Vyzula, CSc. |
MUDr. Igor Kiss, PhD. | MUDr. Štěpán Tuček, PhD. | MUDr. Lucia Šikulíncová | MUDr. Ján Podhorec
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 3 **Nový lék pro personalizovanou léčbu ca prsu Perjeta získal registraci v EU**
- 3 **Pertuzumab**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 2. a 3. LF UK, Praha
- 4 **Antracykliny jako základ standardní léčby pokročilých sarkomů měkkých tkání**
MUDr. Michaela Miškovičová | prof. MUDr. Luboš Petruželka, CSc.
Onkologická klinika VFN a ÚVN 1. LF UK, Praha

Votrient – nový multikinázový inhibitor v léčbě renálního karcinomu

MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha

- 1 **Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.:** Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. *J Clin Oncol*, 2010, 28, s. 1061–1068.
- 2 **Motzer, R. – Hudson, T. E. – Reeves, J., et al.:** Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC): results of the COMPARZ trial. Prezentováno na: 2012 European Society for Medical Oncology, Vídeň, Rakousko, 1. 10. 2012, abstrakt LBA 8.
- 3 **Escudier, B. – Porta, C. – Bono, B., et al.:** Patient preference between pazopanib and sunitinib: Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma – PISCES study, NCT 01064310. *ASCO*, 2012, abstrakt CRA4502.
- 4 **Kaelin, W. G.:** Molecular basis of the VHL hereditary cancer syndrome. *Nat Rev Cancor*, 2002, 2, s. 673–682.
- 5 **Büchler, T. – Klapka, R. – Melichar, B., et al.:** Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. *Ann Oncol*, 2012, 23, 395–401, epub 2. 5. 2011.
- 6 **Iacovelli, R. – Santoni, M. – Di Lorenzo, G., et al.:** Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC). *Ann Oncol*, 2012, 23, abstrakt 818P.

Neuroendokrinní nádory – léčba Sandostatinem LAR

MUDr. Oldřich Louthan IV. interní klinika, Centrum pro neuroendokrinní nádory, Všeobecná fakultní nemocnice, 1. LF UK, Praha

- 1 **Arnold, R. – Simon, B. – Word, M.:** Treatment of neuroendocrine GEP tumours with somatostatin analogues. *Digestion*, 2000, 62, s. 84–91.
- 2 **Klöppel, G. – Couvelard, A. – Perren, A. – Komminoth, P. – McNicol, A.-M. – Nilsson, O., et al.:** ENETS Consensus Guideline for the standards of care in neuroendocrine tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. *Neuroendocrinology*, 2009, 90, s. 162–166.
- 3 **Eriksson, B. – Klöppel, G. – Krenning, E., et al.:** Consensus Guidelines for the management of patients with digestive neuroendocrine tumours—well-differentiated jejunal-ileal tumor/carcinoma. *Neuroendocrinology*, 2008, 87, s. 8–19.
- 4 **Lewington, W. J.:** Targeted radionuclide therapy for neuroendocrine tumour. *Endocrine-Related Cancor*, 2003, 10, s. 497–501.
- 5 **Rinke, A. – Muller, H. H. – Schade-Brittiger, C., et al.:** PROMID Study Group: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *Journal of Clinical Oncology*, 2009, 27, 4656–4663.
- 6 **Bhattacharyya, S. – Davar, J. – Dreyfus, G. – Caplin, M. E.:** Carcinoid heart disease. *Circulation*, 2007, 116, s. 2860–2865.

Pacientka s již primárně diseminovaným HER2 pozitivním karcinomem prsu

MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- 1 **Harris, J. – Lippman, M. E. – Morrow, M. – Osborne, C. K.:** *Diseases of the breast*. 3. vydání, s. 1205–1218.
- 2 **Leyland-Jones, B., et al.:** Incidence of CNS metastases in trastuzumab-treated patients. *J Clin Oncol*, 2009, 27 (31), s. 5278–5286.
- 3 **Anderson, M., et al.:** Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy for metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. *J Clin Oncol*, 2011, 29 (3), s. 264–271.
- 4 **Cameron, D., et al.:** Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. *The Oncologist*, 2010, 15 (9), s. 924–934.
- 5 **Harris, J. – Lippman, M. E. – Morrow, M. – Osborne, C. K.:** *Diseases of the breast*. 3. vydání, s. 1101–1159.
- 6 **Bárteč, R., et al.:** Trastuzumab prolongs overall survival in patients with brain metastases from HER 2 positive breast cancer. *J Neurooncol*, 2007, 85 (3), s. 311–317.
- 7 **Tomasello, G., et al.:** Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. *Crit Rev Oncol Hematol*, 2010, 75 (2), s. 110–121.
- 8 **Pienkowski, T., et al.:** Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. *Ann Oncol*, 2010, 21 (5), s. 917–924.

Pacient s metastatickým kolorektálním karcinomem léčený multimodálním přístupem

MUDr. Andrea Jurečková | MUDr. Jiří Tomášek | prof. MUDr. Rostislav Vyzula, CSc. |
MUDr. Igor Kiss, PhD. | MUDr. Štěpán Tuček, PhD. | MUDr. Lucia Šikulínková | MUDr. Ján Podhorec
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- 1 **Kopetz, S. – Chány, G. J. – Overman, M. J., et al.:** Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *J Clin Oncol*, 2009, 27, s. 3677–3683.
- 2 **Adam, R. – Avisá, E. – Ariche, A., et al.:** Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. *Ann Surg Oncol*, 2001, 8, s. 347–353.
- 3 **Cunningham, D. – Humblet, Y. – Siena, S. – Khayat, D. – Bleiberg, H. – Santoro, A. – Bets, D. – Mueser, M. – Harstrick, A. – Verslype, C., et al.:** Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med*, 2004, 351, s. 337–345.
- 4 **Sobrero, A. F. – Maurel, J. – Fehrenbacher, L., et al.:** EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. *J Clin Oncol*, 2008, 26 (14), s. 2311–2319.
- 5 **Tabernero, J. – Van Cutsem, E. – Díaz-Rubio, E., et al.:** Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol*, 2007, 20, 25 (33), s. 5225–5232.
- 6 **Van Cutsem, E. – Köhne, C. H. – La'ng, I., et al.:** Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol*, 2011, 29, s. 2011–2019.
- 7 **Maughan, T. S. – Adams, R. A. – Smith, C. G., et al.:** Addition of cetuximab to oxaliplatin based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet*, 2011, 377, s. 2103–2114.
- 8 **Tveit, K. M. – Guren, T. – Glimelius, B., et al.:** Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. *J Clin Oncol*, 2012, 30 (15), s. 1755–1762.

Nový lék pro personalizovanou léčbu ca prsu Perjeta získal registraci v EU

- 1 **Dawood, S. et al.:** Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. *J Clin Oncol*, 2010, 28, s. 92–98.
- 2 **Swain, S., et al.:** Confirmatory overall survival analysis of CLEOPATRA: A randomized, double-blind, placebo-controlled Phase III study with pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive first-line metastatic breast cancer. *Cancer Research*, 2012, 72, dopl. 3.
- 3 **Baselga, J. – Cortes, J. – Sung-Bae, K., et al.:** Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*, 2012, 366, s. 109–119.
- 4 **Ferlay, J. – Shin, H. R. – Bray, F. – Forman, D. – Mathers, C. – Parkin, D. M.:** GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, Francie: International Agency for Research on Cancer; 2010. Dostupné z: <http://globocan.iarc.fr>.
- 5 **Wolff, A. C., et al.:** American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *Arch Pathol Lab Med*, 2007, 131.
- 6 **Slamon, D., et al.:** Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*, 2011, 365, s. 1273–1283.

Pertuzumab

MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha

- 1 **Baselga, J.:** Treatment of HER2-overexpressing breast cancer. *Ann Oncol*, 2010, dopl. 7, s. vii 36–40.
- 2 **Perez-García, J. – Muñoz-Couselo, E. – Ortega, V. – Cortes, J.:** The beautiful history of pertuzumab. *Expert Rev Anticancer Ther*, 2012, 12 (6), s. 703–705.
- 3 **Gianni, L. – Pienkowski, T. – Im, Y. H., et al.:** Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2012, 13 (1), s. 25–32.
- 4 **Baselga, J. – Cortés, J. – Kim, S. B., et al.:** Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*, 2012, 366 (2), s. 109–119.
- 5 **Kratiny, G. M.:** Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. *Drugs*, 2012, 72 (3), s. 353–360.

Antracykliny jako základ standardní léčby pokročilých sarkomů měkkých tkání

MUDr. Michaela Miškovičová | prof. MUDr. Luboš Petruželka, CSc.

Onkologická klinika VFN a ÚVN 1. LF UK, Praha

- 1 **Adámková Krákorová, D.:** Systémová léčba sarkomů měkkých tkání dospělých vyjma GIST. *Onkologie*, 2010, 4 (5), s. 308–310.
- 2 **Chen, Y. B. – Guo, L. C. – Yang, L. – Feng, W. – Zhang, X. Q. – Ling, C. H. – Ji, C. – Juany, J. A.:** Angiosarcoma of the lung: 2 cases report and literature reviewed. *Lung Cancer*, 2010, 70 (3), s. 352–356.
- 3 **DeVita, V. T. – Lawrence, T. S. – Rosenberg, S. A.:** *Cancer. Principles and Practice Oncology*. Wolters Kluwer, 2011.
- 4 ESMO clinical practice guidelines. *Annals of Oncology*, 2012, 23 (dopl. 7), s. 92–99.
- 5 **Eriksson, E.:** Histology-driven chemotherapy of soft-tissue sarcoma. *Annals of Oncology*, 2010, 21 (dopl. 7), s. 270–276.
- 6 *NCCN guidelines 2012*.
- 7 **Sleijfer, S. – Seynaeve, C. – Verweij, J.:** Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. *The Oncologist*, 2005, 10, s. 833–841.
- 8 **Veselý, K.:** Histopatologická diagnostika nádorů měkkých tkání. *Onkologie*, 2010, 4 (5), s. 293–296.